SP-103
Acute Lower Back Pain, Chronic Neck Pain
Phase 2Phase 2 completed; planning Phase 2/3
Key Facts
Indication
Acute Lower Back Pain, Chronic Neck Pain
Phase
Phase 2
Status
Phase 2 completed; planning Phase 2/3
Company
About SCILEX
Scilex Holding Company (Nasdaq: SCLX) is a revenue-generating biopharmaceutical company dedicated to becoming a global leader in non-opioid pain management. Its strategy combines the commercialization of acquired, approved products like ZTlido®, Elyxyb®, and Gloperba® with the development of a proprietary pipeline, including the late-stage injectable candidate SEMDEXA™ for sciatica. Founded in 2013 and headquartered in Palo Alto, California, Scilex is positioned at the critical intersection of drug delivery innovation and the urgent societal need to address the opioid crisis.
View full company profile